Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Inflamm Res. 2014 May 30;63(9):703–710. doi: 10.1007/s00011-014-0743-3

Figure 4. Inhibition of ERK1/2 suppresses ICAM-1 and MCP-1 production in human AVICs.

Figure 4

A. Representative immunoblots show that biglycan (BGN, 0.10 μg/mL) induced rapid phosphorylation of ERK1/2, and PD98059 at 20 μmol/L attenuated BGN-induced ERK1/2 phosphorylation. B. Inhibition of ERK1/2 markedly reduced ICAM-1 and MCP-1 production following biglycan stimulation. Values are means ± SE. n = 3; *P<0.05 vs. untreated control; #P<0.05 vs BGN alone.